26
|
Tonini G, Mouysset J, Rotarski M, Spaeth D, Airoldi M, Toganel C, Christofyllakis C, Belton L, Bohac C, Terwey J. Additional Haemoglobin (Hb) and Quality of Life (Qol) Analyses from Eaqua. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu356.30] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
27
|
Bossi P, Russi E, Numico G, De Sanctis V, Denaro N, Ghi M, Mirabile A, Moretto F, Ripamonti C, Buglione M, Airoldi M, Vermorken J, Murphy B, Langendijk J, Raber Durlacher J, Licitra L. Defining Best Practices on Supportive Care During Chemo-Radiotherapy for Head and Neck Cancer with a Formal Systematic Methodology. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu340.6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
28
|
Merlini L, Carteni G, Iacobelli S, Stelitano C, Airoldi M, Balke P, Keil F, Haslbauer F, Belton L, Pujol B. Anemia Point Prevalence in Patients Receiving Chemotherapy in 56 Centers in Italy and Austria. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)34179-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
29
|
Ostellino O, Airoldi M, Garzaro M, Pedani F, Raimondo L, Riva G, Carnio S, Pecorari G, Fora G, Giordano C. Cisplatin + Vinorelbine (DDP + VNB) Administered in 60 Cases of Recurrent/Metastatic Salivary Gland Malignancies (RMSGM): Final Report. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33616-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
30
|
Airoldi M, Garzaro M, Raimondo L, Riva G, Ostellino O, Pecorari G, Giordano C. 8592 POSTER Long Term Quality of Life, Physical and Psychological Functioning in Patients Affected by Relapsed Head and Neck Cancer. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72234-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
31
|
Garzaro M, Raimondo L, Pecorari G, Pedani F, Giordano C, Airoldi M. Comparison of two schedules in locally advanced nasopharyngeal carcinoma observed in a nonendemic population. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.5542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
32
|
Raimondo L, Garzaro M, Riva G, Pecorari G, Giordano C, Airoldi M. Long-term toxicity: A comparison between surgery plus radiotherapy and exclusive chemoradiation therapy regimes in oropharyngeal cancer patients. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.5535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
33
|
Airoldi M, Garzaro M, Raimondo L, Riva G, Pecorari G, Giordano C. Quality of life, physical, and psychologic functioning in patients affected by end-stage head and neck cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.5537] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
34
|
Soria A, Airoldi M, Migliorino G, Squillace N, Bandera A, Lapadula G, Gori A. Lung cryptococcosis in a treated HIV-1-infected patient with suppressed viral load and past disseminated cryptococcosis: relapse or late IRIS? J Antimicrob Chemother 2011; 66:1190-1. [DOI: 10.1093/jac/dkr067] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Riebe B, Karas CS, Bagan B, Baig MN, Hallock A, Hamilton B, Ang CL, Tay K, Megyesi J, Fisher B, Watling C, MacDonald D, Bauman G, Momin E, Adams H, Quinones-Hinojosa A, Ruda R, Bertero L, Picco E, Trevian E, Tarenzi L, Donadio M, Airoldi M, Bertetto O, Mocellini C, Soffietti R, McCarthy BJ, Dolecek TA, Johnson DR, Olson JE, Vierkant RA, Hammack JE, Wang AH, Folsom AR, Virnig BA, Cerhan JR, Scheurer ME, Etzel CJ, Wefel JS, Liu Y, Liang FW, El-Zein R, Meyers CA, Bondy ML, Davis F, Dolecek TA, McCarthy BJ, Hottinger AF, Perez L, Usel M, Neyroud-Caspar I, Bouchardy C, Dietrich PY, Jho DJ, Eltantawy MH, Sekula R, Aziz K, Lee SY, Slagle-Webb B, Sheehan JM, Connor JR, Elena P, Andrew L, Anne R, Katherine P, Lisa D, Lai RK, Ferris J, Florendo E, McCoy L, Rice T, Ottman R, Neugut AI, Wiencke J, Wiemels J, Wrensch M, Yovino S, Hadley C, Kwok Y, Eisenberg H, Regine WF, Feigenberg S, Megyesi JF, Haji F, Patel Y, Ang LC, Lachance DH, Wrensch M, Il'yasova D, Decker P, Johnson D, Xiao Y, Rynearson A, Fink S, Kosel M, Yang P, Fridley B, Wiemels J, Wiencke J, Ali-Osman F, Davis F, Kollmeyer T, Buckner J, O'Neill B, Jenkins R. Epidemiology. Neuro Oncol 2010. [DOI: 10.1093/neuonc/noq116.s3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Airoldi M, Garzaro M, Raimondo L, Pecorari G, Giordano C. A comparison between surgery plus radiotherapy and exclusive chemoradiation therapy regimes in oral and oropharyngeal cancer: Long-term functional and psychological impact. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.5575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
37
|
Numico G, Airoldi M, Gabriele P, Gabriele A, Garzaro M, Raimondo L, Pedani F, Beatrice F, Pecorari G, Giordano C. Induction chemotherapy with carboplatin and paclitaxel followed by radiotherapy and concurrent weekly carboplatin plus paclitaxel in locally advanced nasopharyngeal carcinoma in a nonendemic population. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.5569] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
38
|
Rudà R, Bertero L, Picco E, Trevisan E, Tarenzi L, Donadio M, Airoldi M, Bertetto O, Mocellini C, Soffietti R. Frequency, patterns of care, and outcome of neoplastic meningitis (NM) from solid tumors in regione Piemonte, Italy: A prospective survey from a cancer network. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e12530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
39
|
Gabriele A, Airoldi M, Garzaro M, Raimondo L, Pedani F, Beatrice F, Pecorari G, Giordano C. 8556 Induction chemotherapy with carboplatin and taxol followed by radiotherapy and concurrent weekly carboplatin + taxol in locally advanced nasopharyngeal carcinoma. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71647-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
40
|
Airoldi M, Garzaro M, Raimondo L, Gabriele A, Giordano C. 8555 Induction chemotherapy with cysplatin and epirubicin followed by radiotherapy and concurrent cysplatin in locally advanced nasopharyngeal carcinoma observed in a non-endemic population. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71646-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
41
|
Raimondo L, Airoldi M, Garzaro M, Pecorari G, Caldera P, Varetto A, Torta R, Giordano C. 8569 Neoadjuvant chemotherapy plus concomitant chemoradiotherapy in head and neck cancer: late toxicity and impact on quality of life. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71660-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
42
|
Zanon C, Airoldi M, Garzaro M, Raimondo L. Functional and psychological evaluation after exclusive chemoradiation therapy in oral and oropharyngeal cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e17012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e17012 Purpose: The treatment of head and neck tumours often negatively affects speech, swallowing, body image and quality of life (QoL). Aim of this study was the evaluation of the impact of exclusive chemoradiation therapy (CH-RT) on QoL and psychological functioning. Patients and Methods: Twenty-eight patients, affected by a carcinoma of the oral cavity and oropharynx received exclusive CH-RT. Late effects of CH-RT and psycho-oncological assessment included: Radiation Therapy Oncology Group (RTOG) - European Organisation for Research and Treatment of Cancer (EORTC) late radiation morbidity scoring system, DISCHE morbidity recording scheme, Hospital Anxiety and Depression Scale (HADS), Montgomery Asberg Depression Rating Scale (MADRS), Mini Mental Adjustment to Cancer (MINI MAC), and EORTC QoL Head and Neck 35. Results: After a median follow-up of 42 months (range 12–60 months) moderate-severe late toxicity was as follows: taste impairment (89.20%), salivary function (82.12%), subcutaneous tissue (7.08%). Concerning dysphagia 39% of patients complained some discomfort, 28% had a more severe toxicity whereas 7% could not have an oral feeding; patients with severe dysphagia showed higher levels of anxiety (p < 0.05): dysphagia influences the QoL, fatigue and physical-social functioning. Rates of depression and anxiety were generally low: 78.6% of our sample did not show clinical relevant anxious symptoms and 82.1% of patients did not reach the threshold of an overt depression. Just a fair concordance in rate of depression between self- and hetero-evaluated scale was observed, with higher rates relieved by MADRS compare to HADS depression subscale using 8 or 10 cut-off (Cohen's k test = 0.401) Conclusions: Our data suggest low rates of anxiety and depression, in patients treated with CH-RT, with a different evaluation between self-evaluative and hetero-evaluative scales. No significant financial relationships to disclose.
Collapse
|
43
|
Airoldi M, Garzaro M, Gabriele A, Raimondo L. Induction chemotherapy with cisplatin and epirubicin followed by radiotherapy and concurrent cisplatin in locally advanced nasopharyngeal carcinoma observed in a nonendemic population. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e17040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e17040 Background: Chemoradiotherapy (CRT) represents the main therapy choice in the treatment of locoregionally advanced nasopharyngeal carcinoma (NPC). Aim of this study was the clinical evaluation of neoadjuvant chemotherapy (NACT) followed by CRT in a non endemic population affected by advanced NPC. Methods: Patients with locoregionally advanced NPC were treated with three cycles of induction chemotherapy (CHT) with cisplatin (100 mg/m2) plus epirubicin (90 mg/m2), followed by cisplatin (100 mg/m2) and concomitant radiotherapy (70 Gy). Results: In 40 patients treated with such protocol, after the completion of induction CHT and CRT we observed the objective response rates of 90% and 100% respectively. Treatment tolerability and toxicity were easily controllable. With a median follow-up time of 54.5 months 3- and 5-years disease-free survival was 75% and 65.4% and 3- and 5-years overall survival was 84% and 77.5%. 3- and 5-years loco-regional control was 82.4% and 70.3%, and 5-years distant metastases-free survival was 75%. Conclusions: NACT with cisplatin and epirubicin followed by concomitant CRT represents a feasible, efficient treatment for patients with advanced NPC. This regimen ensures an excellent locoregional disease control and overall survival with a low incidence of distant metastases. No significant financial relationships to disclose.
Collapse
|
44
|
Garzaro M, Airoldi M, Raimondo L, Pecorari G, Giordano C, Caldera P, Varetto A, Zanon C, Torta R. Long-term quality of life and psychological response after flap reconstructive surgery and radiotherapy in head and neck cancer patients. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.20553] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
45
|
Airoldi M, Cattel L, Milla P, Passera R, Pedani F, Crova A. Parmacokinetics (PK) of oral vinorelbine (VNR) in association with pegylated liposomal doxorubicin (PLD) in metastatic ovarian carcinoma. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.13531] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
46
|
Cattel L, Airoldi M, Delprino L, Passera R, Milla P, Pedani F. Pharmacokinetic evaluation of gemcitabine and 2',2'-difluorodeoxycytidine-5'-triphosphate after prolonged infusion in patients affected by different solid tumors. Ann Oncol 2008; 17 Suppl 5:v142-7. [PMID: 16807444 DOI: 10.1093/annonc/mdj970] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND The study determined pharmacokinetic parameters, toxicity profile and preliminary clinical activity of gemcitabine administered i.v. at different infusion rates in patients with a range of solid tumors. PATIENTS AND METHODS Twenty patients were enrolled for both pharmacokinetic and clinical studies. Gemcitabine 300 mg/m(2) was administered during 1 h, 2 h or 3 h, and as a conventional dose of 1000 mg/m(2) during 30 min infusion. Administration was on days 1, 8 and 15 every 4 weeks. RESULTS Patients were randomly assigned to one of the four arms. After 30 min infusion of 1000 mg/m(2) gemcitabine the plasma concentration remained above the saturation level of 10-20 microM, whereas after 1, 2 or 3 h infusion 300 mg/m(2) gemcitabine it remained below the saturation level for most of the time (being in the range 2.5-10 microM). Gemcitabine triphosphate was determined in the four arms in white blood cells; for infusion times from 0.5 to 3 h there was a progressive enhancement of gemcitabine triphosphate levels. In all evaluable patients the toxicity was mild, myelosuppression being the main toxicity. No grade 3 or 4 toxicities occurred. Clinical response was similar in patients receiving 300 mg/m(2) gemcitabine in 2 and 3 h and in the 1000 mg/m(2) arm. CONCLUSIONS 300 mg/m(2) gemcitabine during 3 h infusion produced the highest accumulation of gemcitabine triphosphate. Thus, to achieve the highest possible gemcitabine triphosphate level, prolonged infusion time would appear to be more important than a high dose administered as a short infusion. However, there was no substantial difference in toxicity or antitumoral activity in the all different patient groups.
Collapse
|
47
|
Maggiolo F, Airoldi M, Trotta MP, Sette P, Bisi L, Mussini C, Bai F, Bini T, Orofino G, Gori A. Effect of a fixed-dose combination of emtricitabine, tenofovir and efavirenz on adherence and treatment acceptability (ADONE study). J Int AIDS Soc 2008. [DOI: 10.1186/1758-2652-11-s1-p167] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
48
|
Maggiolo F, Airoldi M, Callegaro A, Martinelli C, Dolara A, Bini T, Gregis G, Quinzan P, Ravasio V, Suter F. O213 CD4-guided STI in patients responding to HAART. J Int AIDS Soc 2008. [DOI: 10.1186/1758-2652-11-s1-o18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
49
|
Airoldi M, Cattel L, Milla P, Cerutti E, Pedani F, Crova A. 5522 POSTER Paclitaxel and pegylated liposomal doxorubicin association: effects of different administration intervals on the pharmacokinetics. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)71239-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
50
|
Lorusso D, Fornari G, Caponigro F, Quirino M, Merlano M, Airoldi M, Schena M, Jannuzzo M, Crippa S, Scambia G. 715 POSTER Phase I dose-escalation study of brostallicin in combination with cisplatin (cDDP) in patients with advanced solid tumors. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)70514-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|